Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 25;9:616893. doi: 10.3389/fcell.2021.616893

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Eremichev, Kulebyakina, Alexandrushkina, Nimiritsky, Basalova, Grigorieva, Egiazaryan, Dyikanov, Tkachuk and Makarevich.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Treatment with transforming growth factor β1 (TGF-β1) induces SMAD2 signaling in stromal cells from the endometrium (EndoSCs), dermis (DermSCs), and adipose tissue (AdipoSCs). (A) Representative Western blotting of EndoSC, DermSC, and AdipoSC lysates obtained before TGF-β1 treatment (lane “0”), at 96 h in control culture (lane 96/–), or at 96 h after addition of 10 ng/ml TGF-β1 (lane 96/+). (B) Densitometry analysis of Western blotting for pSMAD2 in stromal cells demonstrating the effect of TGF-β1. Individual donor (n = 3) data presented as fold change relative to the level before TGF-β1 treatment (logarithmic scale) with SMAD2 loading control used for normalization. Paired t-test was used for statistical analysis of log-transformed data; ^∗p < 0.05.